or Try an Advanced Search...

    Technical Analysis for GELS - Gelteq Limited

    Grade Last Price % Change Price Change
    D 2.65 26.19% 0.55
    GELS closed up 26.19 percent on Wednesday, January 22, 2025, on 12.6 times normal volume. The stock rose above its 50 day moving average, improving its intermediate-term outlook by crossing above that important trendline.
    0 Watchers
    Watchlist Portfolio

    Trend Table & Recent EOD Trading Signals

    ADX Long Term Intermediate Term Short Term
    Weak or Absent N/A Up Up
    Historical GELS trend table...
    Date Alert Name Type % Chg
    Crossed Above 20 DMA Bullish 0.00%
    Crossed Above 50 DMA Bullish 0.00%
    MACD Bullish Signal Line Cross Bullish 0.00%
    Expansion Pivot Buy Setup Bullish Swing Setup 0.00%
    Pocket Pivot Bullish Swing Setup 0.00%
    Volume Surge Other 0.00%
    Wide Bands Range Expansion 0.00%
    Gapped Up Strength 0.00%
    Upper Bollinger Band Touch Strength 0.00%
    Outside Day Range Expansion 26.19%
    Older End-of-Day Signals for GELS ...

       Recent Intraday Alerts

    Alert Time
    Rose Above 20 DMA about 23 hours ago
    20 DMA Support about 23 hours ago
    50 DMA Support about 23 hours ago
    Rose Above Previous Day's High about 23 hours ago
    Rose Above Upper Bollinger Band about 23 hours ago
    View Earlier Intraday Alerts

    Get this analysis on your stocks daily!

    Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
    Read My Charts!
    GELS Chart by TradingView

    Profile

    • Earnings date: Unknown
    Gelteq Ltd. is a biotechnology company. It focuses on the development and commercialization of white label gel-based delivery solutions for prescription drugs, nutraceuticals, pet care, and other products. The firm also offers edible gels. The company was founded by Nathan J. Givoni and Simon H. Szewach on October 15, 2018 and is headquartered in Melbourne, Australia.
    Classification
    Sector: Healthcare
    Industry: Drug Manufacturers - Specialty & Generic
    Keywords: Biotechnology Nutraceutical Physical Chemistry

    Is GELS a Buy, Sell or Hold?

    Indicator Bull Case Neutral / Hold Bear Case
    50 DMA
    200 DMA
    ADX Trend
    Oversold / Overbought
    Relative Strength
    Counts: 1 bullish, 1 bearish and 3 neutral indicators. You may wish to incorporate that into your trading strategies.

    Recent News

    Date Title
    Dec 19 Gelteq Appoints Dr. Paul Wynne as Chief Scientific Officer to Propel Innovative Ingestible Gel Technology
    Dec 17 Gelteq Receives FDA Approval of its Suitability Petition for New Animal Drug
    Dec 10 Why C3.ai Shares Are Trading Higher By Around 8%; Here Are 20 Stocks Moving Premarket
    Dec 9 Gelteq to Participate in the Benchmark Company 13th Annual Discovery Investor Conference
    Dec 3 Why Credo Technology Group Shares Are Trading Higher By 40%; Here Are 20 Stocks Moving Premarket
    Dec 2 Gelteq’s largest U.S. customer increases initial order by 50%
    Dec 2 Gelteq Announces Largest U.S. Customer Increases Initial Order by 50% to Meet Growing Market Demand
    Nov 12 Gelteq Expands Operations in United States with Appointment of Adam Bendell as President of U.S. Operations to Scale Domestic Business
    Oct 29 Biotech company Gelteq prices IPO at $4 per share
    Oct 28 IPO Roundup: Brazil Potash, Septerna and more
    See more GELS news...

    Comments

    Indicators

    Indicator Value
    52 Week High 5.5
    52 Week Low 1.42
    Average Volume 588,231
    200-Day Moving Average 0.00
    50-Day Moving Average 2.38
    20-Day Moving Average 2.32
    10-Day Moving Average 2.22
    Average True Range 0.45
    RSI (14) 55.36
    ADX 16.03
    +DI 22.99
    -DI 16.74
    Chandelier Exit (Long, 3 ATRs) 1.95
    Chandelier Exit (Short, 3 ATRs) 3.22
    Upper Bollinger Bands 2.69
    Lower Bollinger Band 1.95
    Percent B (%b) 0.95
    BandWidth 31.67
    MACD Line -0.08
    MACD Signal Line -0.09
    MACD Histogram 0.0087
    Fundamentals Value
    Market Cap 25.01 Million
    Num Shares 9.44 Million
    EPS -0.23
    Price-to-Earnings (P/E) Ratio -11.52
    Price-to-Sales 154.01
    Price-to-Book 2.15
    Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
    Resistance 4 (R4) 3.48
    Resistance 3 (R3) 3.43 3.12 3.34
    Resistance 2 (R2) 3.12 2.91 3.14 3.29
    Resistance 1 (R1) 2.88 2.78 3.00 2.93 3.25
    Pivot Point 2.57 2.57 2.63 2.59 2.57
    Support 1 (S1) 2.33 2.36 2.45 2.38 2.05
    Support 2 (S2) 2.02 2.23 2.04 2.01
    Support 3 (S3) 1.78 2.02 1.96
    Support 4 (S4) 1.83